300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Marketplace
Retail
Film
Payments
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
United Kingdom
Egypt
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oceania
Argentina
Oman
Tunisia
Taiwan
Zimbabwe
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
HTL Biotechnology, VC Fund

HTL Biotechnology

VC Fund

Javené, France

HTL Biotechnology is a VC fund in Javené focused on Health Care and Biotechnology. HTL is a manufacturer and research & development of Hyaluronan and other biological polymers by bacterial fermentation.HTL SAS was created in 1992 and is specialized in the manufacture, purification and research and development of Hyaluronan (HA). Today it has diversified and produces other biological polymers (see new products) for thepharmaceutical and medical fields.

Total investments:
2
Last investment:
Lead investor:
0%

Last updated:

Industries HTL Biotechnology invests in

Health CareBiotechnologyMedical DevicePharmaceutical

Stages HTL Biotechnology invests in

Seed

Countries HTL Biotechnology invests in

FranceUnited States

Contacts

NameEmailPhoneSocials
Cyril Picault Cyril Picault
Glenn Prestwich Glenn Prestwich
Susanne Liepmann Susanne Liepmann
Yvon Bastard Yvon Bastard

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 2 (100%)
  • Biotechnology 2 (100%)
  • Medical Device 1 (50%)
  • Pharmaceutical 1 (50%)

Country

  • France 1 (50%)
  • United States 1 (50%)

Team

NameTitleInvestmentsLinksEmail
Cyril Picault
Cyril Picault Chief Operating Officer
Chief Operating Officer Total investments: 0 Find email
Glenn Prestwich
Glenn Prestwich Science & Innovation Advisor
Science & Innovation Advisor Total investments: 0 Find email
Susanne Liepmann
Susanne Liepmann Group CFO
Group CFO Total investments: 0 Find email
Yvon Bastard
Yvon Bastard Chief Executive Officer & Président-Directeur Général
Chief Executive Officer & Président-Directeur Général Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Gelmedix Gelmedix
Gelmedix is a developer of a biomaterial platform to improve drug delivery for complicated ophthalmic treatment. The company's platform offers a single non-invasive gel patch that can be used as a drug-eluting sealant with tissue adhesion, tunable drug elution, and biocompatibility properties, thereby enabling healthcare providers to reducethe usage of drops which cause inconvenience to patients. $13M / Seed / Feb 17, 2026
BIOPHTA BIOPHTA
BIOPHTA has pioneered a new approach to eye care by creating a cutting-edge pharmaceutical platform that enables continuous drug delivery. Their non-invasive topical ocular inserts represent a significant advancement in the treatment of many ophthalmic disorders, providing superior long-term disease management. $7.1M / Seed / Jun 03, 2024

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Marketplace
Retail
Film
Payments
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
United Kingdom
Egypt
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oceania
Argentina
Oman
Tunisia
Taiwan
Zimbabwe
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does HTL Biotechnology invest in?

HTL Biotechnology invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact HTL Biotechnology?

Public channels for HTL Biotechnology include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at HTL Biotechnology?

The team at HTL Biotechnology includes Cyril Picault (Chief Operating Officer), Glenn Prestwich (Science & Innovation Advisor) and Susanne Liepmann (Group CFO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
HTL Biotechnology HTL Biotechnology Find emails